Immunohistochemical expression profiles found that tumor-infiltrating CD4+ T cells statistically-significantly increased after treatment of these lung cancers with the combined regimen as compared to vehicle-treatments (Fig. 4c,d). This evidence concerns the gene CD4 and lung cancer.